(Q53306420)

13 May 2018

title

Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. (English)

1 reference

13 May 2018

non-small-cell lung carcinoma

main subject

1 reference

Zafer Cetin

1

1 reference

13 May 2018

Gulay Ozbilim

2

1 reference

13 May 2018

Abdullah Erdogan

3

1 reference

13 May 2018

Guven Luleci

4

1 reference

13 May 2018

Sibel Berker Karauzum

5

1 reference

13 May 2018

publication date

10 September 2009

1 reference

13 May 2018

published in

Medical Oncology

1 reference

13 May 2018

volume

27

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

853-860

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s12032-009-9296-7

exact match

0 references

cites work

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

New molecularly targeted therapies for lung cancer

1 reference

12 December 2020

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

1 reference

12 December 2020

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

1 reference

12 December 2020

Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy

1 reference

12 December 2020

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

1 reference

12 December 2020

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer

1 reference

12 December 2020

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

1 reference

12 December 2020

PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer

1 reference

12 December 2020

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

1 reference

12 December 2020

A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells

1 reference

12 December 2020

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

12 December 2020

EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer

1 reference

12 December 2020

Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC.

1 reference

12 December 2020

Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer

1 reference

12 December 2020

Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

1 reference

12 December 2020

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer

1 reference

12 December 2020

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

1 reference

12 December 2020

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Targeted therapies in lung cancer.

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation

1 reference

12 December 2020

Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.

1 reference

12 December 2020

Impact of EGFR mutation analysis in non-small cell lung cancer.

1 reference

12 December 2020

Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S12032-009-9296-7

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018